Šalis: Jungtinės Valstijos
kalba: anglų
Šaltinis: NLM (National Library of Medicine)
DOCETAXEL ANHYDROUS (UNII: 699121PHCA) (DOCETAXEL ANHYDROUS - UNII:699121PHCA)
Sun Pharmaceutical Industries, Inc.
INTRAVENOUS
PRESCRIPTION DRUG
DOCETAXEL INJECTION is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. DOCETAXEL INJECTION in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. DOCETAXEL INJECTION as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. DOCETAXEL INJECTION in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. DOCETAXEL INJECTION in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. DOCETAXEL INJECTION in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga
DOCETAXEL INJECTION is supplied in a single-dose vial for 20 mg/mL, single-dose vial for 80 mg/4 mL and single-dose vial for 160 mg/8 mL as a sterile, pyrogen-free, non-aqueous solution. Discard unused portion. DOCETAXEL INJECTION 20 mg/mL: NDC 47335-323-40 The vial is in a blister pack in one carton. DOCETAXEL INJECTION 80 mg/4 mL: NDC 47335-895-40 The vial is in a blister pack in one carton. DOCETAXEL INJECTION 160 mg/8 mL: NDC 47335-939-40 The vial is in a blister pack in one carton. Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Retain in the original package to protect from light. DOCETAXEL INJECTION is a cytotoxic drug. Follow applicable special handling and disposal procedures.1
New Drug Application
DOCETAXEL - DOCETAXEL INJECTION, SOLUTION SUN PHARMACEUTICAL INDUSTRIES, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DOCETAXEL INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DOCETAXEL INJECTION. DOCETAXEL INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1996 WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, AND FLUID RETENTION _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ • TREATMENT-RELATED MORTALITY INCREASES WITH ABNORMAL LIVER FUNCTION, AT HIGHER DOSES, AND IN PATIENTS WITH NSCLC AND PRIOR PLATINUM-BASED THERAPY RECEIVING DOCETAXEL AT 100 MG/M2 (5.1) • AVOID USE OF DOCETAXEL INJECTION IF BILIRUBIN > ULN, OR IF AST AND/OR ALT > 1.5 X ULN CONCOMITANT WITH ALKALINE PHOSPHATASE > 2.5 X ULN. LFT ELEVATIONS INCREASE RISK OF SEVERE OR LIFE-THREATENING COMPLICATIONS. OBTAIN LFTS BEFORE EACH TREATMENT CYCLE (5.2) • DO NOT ADMINISTER DOCETAXEL INJECTION TO PATIENTS WITH NEUTROPHIL COUNTS <1,500 CELLS/MM3. OBTAIN FREQUENT BLOOD COUNTS TO MONITOR FOR NEUTROPENIA (4, 5.3) • SEVERE HYPERSENSITIVITY, INCLUDING FATAL ANAPHYLAXIS, HAS BEEN REPORTED IN PATIENTS WHO RECEIVED DEXAMETHASONE PREMEDICATION. SEVERE REACTIONS REQUIRE IMMEDIATE DISCONTINUATION OF DOCETAXEL INJECTION AND ADMINISTRATION OF APPROPRIATE THERAPY (5.5) • CONTRAINDICATED IF HISTORY OF SEVERE HYPERSENSITIVITY REACTIONS TO DOCETAXEL OR TO DRUGS FORMULATED WITH POLYSORBATE 80 (4) • SEVERE FLUID RETENTION MAY OCCUR DESPITE DEXAMETHASONE (5.6) RECENT MAJOR CHANGES Warnings and Precautions (5.2, 5.7, 5.8, 5.12) 2/2020 Warnings and Precautions (5.14) 2/2021 INDICATIONS AND USAGE DOCETAXEL INJECTION is a microtubule inhibitor indicated for: (1) BREAST CANCER (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) NON-SMALL CELL LUNG CANCER (NSCLC): single agent for locally advanc Perskaitykite visą dokumentą